SchistoShield®血吸虫病疫苗在未感染与流行区人群中诱导抗体介导的功能性反应
本研究检测了SchistoShield®疫苗在美国及非洲两国临床试验受试者血清中的特异性总IgG抗体滴度,并评估疫苗诱导抗体的体外杀虫与小鼠被动转移保护作用。结果显示总IgG于首次加强后第5周升高、第9和12周达峰,美、布基纳法索、马达加斯加受试者血清体外杀虫率分别为69.2%、55.1%、34.3%,被动转移可降低小鼠虫负荷、虫卵计数及孵化能力。
要点
- SchistoShield®可诱导特异性总IgG,首次加强后第5周升高,第9和12周达峰。
- 美国、布基纳法索、马达加斯加受试者血清体外杀虫率分别为69.2%、55.1%、34.3%。
- 疫苗受试者总IgG被动转移可降低小鼠虫负荷、虫卵计数和孵化能力。
核心结论
- SchistoShield®可诱导产生功能性抗体,可能在抗体介导的血吸虫病保护中起关键作用。
研究设计与样本
- 检测美国及非洲两国(马达加斯加、布基纳法索)SchistoShield®临床试验受试者多个时间点血清总IgG滴度。
- 开展体外血吸虫童虫杀伤试验及纯化总IgG小鼠异体被动转移实验以评估疫苗诱导抗体功能。
主要发现
- 总IgG滴度于首次加强后第5周升高,第9和12周达峰。
- 美国、布基纳法索、马达加斯加受试者血清体外童虫杀伤率分别为69.2%、55.1%、34.3%。
- 与接种前血清组相比,疫苗接种者总IgG被动转移至小鼠后虫负荷、虫卵计数及虫卵孵化能力均显著降低。
临床怎么用
- 提示SchistoShield®诱导的抗体具有体外杀虫和小鼠体内减虫减卵功能,支持进一步临床开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Schistosomiasis (bilharzia) is a neglected tropical disease caused by Schistosoma spp. Clinical manifestation of chronic schistosomiasis include but not restricted to anemia, growth stunting, hepatosplenomegaly, cognitive impairment in children and male/female genital schistosomiasis. Praziquantel (PZQ) remains the principal standard treatment for schistosomiasis, but concerns about its reduced effectiveness against larval stages, reinfections, and emerging drug resistance reinforces the urgent need for a vaccine. SchistoShield®, composed of Sm-p80 antigen with GLA-SE adjuvant, is a promising vaccine candidate that has successfully completed phase 1 and 1b clinical trials in the USA and two countries in Africa (Madagascar and Burkina Faso). In this study, SchistoShield® vaccine specific total IgG antibody titers were measured from serum samples collected at multiple time points from both the USA and Africa trials. Results demonstrate that total IgG titers increased at week 5 after the first booster and peaked at weeks 9 and 12. Furthermore, in vitro schistosomula killing assays and heterologous passive transfer of purified total IgG in mice were performed to evaluate the role of vaccine-induced antibodies against schistosomes. Sera collected from individuals enrolled in the USA, Burkina Faso, and Madagascar trials, exhibited 69.2%, 55.1%, and 34.3% in vitro schistosomula killing, respectively, indicative of potent anti-worm antibody responses. Passive transfer of human total IgG from vaccinated individuals in mice revealed notable reductions in worm burden, egg counts, and egg-hatching ability compared to groups given pre-vaccination sera across all trials. Overall, these findings support that SchistoShield® induces generation of functional antibodies that may play a crucial role in antibody-mediated protection against schistosomiasis.
引用
- Kalyanasundaram A, Kifle DW, Davis J, et al. Antibody-mediated functional responses induced by the SchistoShield® schistosomiasis vaccine in disease-naïve and endemic human populations. Vaccine. 2026. PMID: 42705169. doi:10.1016/j.vaccine.2026.129129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。